Skip to content

Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying

Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01956682
Enrollment
132
Registered
2013-10-08
Start date
2014-10-31
Completion date
2015-03-31
Last updated
2015-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Regurgitation, Gastric

Brief summary

The primary objective of this trial is to show that an hypoallergenic infant starter formula containing starch and the probiotic L. reuteri decreases the severity of regurgitation/spitting-up in infants presenting regurgitation/spitting-up , and who have taken it for 4 weeks, in comparison with a standard infant starter formula.

Detailed description

The primary objective of this trial is to show that the test formula (HA formula + starch + L. reuteri) decreases the severity (frequency + volume) of regurgitation/spitting-up in infants and ultrasound gastric emptying time, compared to a classical infant starter formula.

Interventions

DIETARY_SUPPLEMENTHA formula + starch + L. reuteri

Sponsors

University of Bari
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
5 Days to 5 Months
Healthy volunteers
Yes

Inclusion criteria

* Full term infant (37 weeks ≤ gestation ≤ 42 weeks) * Age of infant between 5 days and 5 months * NGA * Infant exclusively formula-fed at enrollment * Presenting regurgitation/spitting-up according to the parents' perception * Vandenplas score of at least 2 and maximum 5 * Having obtained the subject's legal representative's written informed consent

Exclusion criteria

* Previous antireflux treatment * Previous consumption of AR infant formula or external thickener * Previous consumption of a formula with L. reuteri * Cow's milk allergy symptoms according to medical decision * Congenital illness or malformation that may affect growth * Significant pre-natal and/or post-natal disease * Newborn whose parents / caregivers cannot be expected to comply with study procedures * Newborn currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study.

Design outcomes

Primary

MeasureTime frameDescription
Regurgitationfour weeks of treatmentThe primary outcome is the difference in the proportions of improved subjects at four weeks of treatment between the treatment and control groups.

Secondary

MeasureTime frameDescription
Regurgitation scoreFour weeks treatmentTo assess the severity of regurgitation/spitting-up To assess the frequency of regurgitation/spitting-up To assess the volume of regurgitation/spitting-up
Gastric empty rateFour week treatmentTo compare the ultrasound gastric empty rate
Digestive toleranceFour weeks treatmentTo assess the infants' digestive tolerance
GrowthFour weeks of treatmentTo assess whether the groups have comparable growth
compliancefour weeks interventionTo assess the subject's compliance to product consumption.
Financial and non-financial burdenFour week treatmentTo measure family financial and non-financial burden related with the regurgitation
Stool frequencyFour weeks treatmentTo assess stool frequency

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026